RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ALX Oncology Holdings Stock

ALX Oncology Holdings Liabilities 2024

ALX Oncology Holdings Liabilities

52.84 M USD

Ticker

ALXO

ISIN

US00166B1052

WKN

A2P79Z

In 2024, ALX Oncology Holdings's total liabilities amounted to 52.84 M USD, a 22.89% difference from the 43 M USD total liabilities in the previous year.

ALX Oncology Holdings Aktienanalyse

What does ALX Oncology Holdings do?

ALX Oncology Holdings Inc is a biopharmaceutical company specializing in the development and commercialization of immunotherapy products for the treatment of cancer. The company was founded in 2015 and is headquartered in Burlingame, California. It is listed on the NASDAQ stock exchange under the ticker symbol "ALXO." History ALX Oncology Holdings Inc was founded by Therese S. Wagner, a respected oncologist with extensive experience in cancer research. The company began its activities with a strong vision focused on developing targeted and effective treatments for cancer patients. Business Model ALX Oncology Holdings Inc is working on the development of immunotherapy products based on two mechanisms of action - inhibition of the CD47 molecule and activation of the myeloid cells of the immune system. The goal is to eliminate cancer cells by enabling them to be recognized and attacked by the immune system. This business model has the potential to improve both the effectiveness and versatility of cancer treatment. Divisions ALX Oncology Holdings Inc operates in several areas, including: Main products: • ALX148 - A monoclonal antibody that acts as a CD47 inhibitor • ALX148-Bispecifics - Two binding domains that contribute to the activation of the myeloid cells of the immune system In addition, ALX Oncology Holdings Inc collaborates with various partners to develop new drugs and therapies. These partnerships include both academic institutions and pharmaceutical companies. Products ALX148 is the flagship product of ALX Oncology. It is a monoclonal antibody that inhibits the CD47 molecule found on the surface of cancer cells, preventing their recognition by the immune system. By inhibiting CD47, the immune system can recognize and destroy cancer cells. ALX148-Bispecifics are antibody-drug conjugates (ADC) and bispecific antibodies (BsAb) that have been developed to activate the myeloid cells in the immune system by combining CD47 inhibitory capabilities with the activation of macrophage-associated ligands (CD40 and CD80). This results in a stronger immune response to cancer cells, leading to their destruction. Summary ALX Oncology Holdings Inc is a biotechnology company specializing in the development and commercialization of immunotherapy products for the treatment of cancer. Their products, ALX148 and ALX148-Bispecifics, inhibit the CD47 molecule and activate the immune system to fight cancer cells. The company collaborates with various partners and has the potential to provide new hope for people with cancer. ALX Oncology Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing ALX Oncology Holdings's Liabilities

ALX Oncology Holdings's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating ALX Oncology Holdings's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing ALX Oncology Holdings's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

ALX Oncology Holdings's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in ALX Oncology Holdings’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about ALX Oncology Holdings stock

What is the level of liabilities of ALX Oncology Holdings this year?

ALX Oncology Holdings has a debt balance of 52.84 M USD this year.

What were the liabilities of ALX Oncology Holdings compared to the previous year?

The liabilities of ALX Oncology Holdings have increased by 22.89% increased compared to the previous year.

What are the consequences of high debt for investors of ALX Oncology Holdings?

High liabilities can pose a risk for investors of ALX Oncology Holdings, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in ALX Oncology Holdings?

Low liabilities mean that ALX Oncology Holdings has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of ALX Oncology Holdings affect the company?

An increase in liabilities of ALX Oncology Holdings can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of ALX Oncology Holdings affect the company?

A decrease in the liabilities of ALX Oncology Holdings can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of ALX Oncology Holdings?

Some factors that can influence the liabilities of ALX Oncology Holdings include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of ALX Oncology Holdings so important for investors?

The liabilities of ALX Oncology Holdings are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can ALX Oncology Holdings take to modify the liabilities?

To change its liabilities, ALX Oncology Holdings can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does ALX Oncology Holdings pay?

Over the past 12 months, ALX Oncology Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ALX Oncology Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of ALX Oncology Holdings?

The current dividend yield of ALX Oncology Holdings is .

When does ALX Oncology Holdings pay dividends?

ALX Oncology Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ALX Oncology Holdings?

ALX Oncology Holdings paid dividends every year for the past 0 years.

What is the dividend of ALX Oncology Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ALX Oncology Holdings located?

ALX Oncology Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von ALX Oncology Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ALX Oncology Holdings from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did ALX Oncology Holdings pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of ALX Oncology Holdings in the year 2023?

In the year 2023, ALX Oncology Holdings distributed 0 USD as dividends.

In which currency does ALX Oncology Holdings pay out the dividend?

The dividends of ALX Oncology Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ALX Oncology Holdings

Our stock analysis for ALX Oncology Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ALX Oncology Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.